RESUMEN
Hormone-associated meningiomas tend to stop growing or decrease in size after cessation of certain progestins, mainly cyproterone acetate. We report three observations on the natural history of hormone-associated intraosseous meningiomas, showing in a first patient that those tumors may grow rapidly under nomegestrol. We then demonstrate the sustained growth of intraosseous hormone-associated meningiomas after cessation of promesgestone and nomegestrol, independently of the intracranial portion, which concurrently decreased in size in the second case or was resected at the time of nomegestrol withdrawal in the third case, thus giving new insights into the tumorigenesis mechanisms of hormone-associated intraosseous meningiomas.
Asunto(s)
Neoplasias Meníngeas/tratamiento farmacológico , Neoplasias Meníngeas/patología , Meningioma/tratamiento farmacológico , Meningioma/patología , Progestinas/uso terapéutico , Proliferación Celular/efectos de los fármacos , Acetato de Ciproterona/uso terapéutico , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Megestrol/análogos & derivados , Megestrol/uso terapéutico , Neoplasias Meníngeas/diagnóstico por imagen , Meningioma/diagnóstico por imagen , Persona de Mediana EdadRESUMEN
OBJECTIVES: A few observational studies have suggested that progesterone and dydrogesterone may have a lower risk of breast cancer than other progestogens. In our earlier xenograft animal experiments, progesterone did not stimulate breast tumors. The aim of this study was to test dydrogesterone for the first time. The study also evaluated the effects of PGRMC1 on proliferation with progestogens. METHODS (1): In-vitro study. The proliferative effects of dydrogesterone and of progesterone were assessed in vitro using T47D cells transfected with PGRMC1 or empty vector in the presence or absence of estradiol. Additionally, to find the strongest proliferator for inclusion as a comparator in the xenograft animal study, norethisterone, levonorgestrel, desogestrel, dienogest, drospirenone, nomegestrol, and cyproterone acetate were tested. METHODS (2): Xenograft main study. PGRMC1-transfected or empty-vector T47D and MCF7 xenotransplants were each treated with four different hormonal preparations: E2+placebo; E2+dydrogesterone; E2+progesterone; E2+norethisterone. A total of 112 castrated mice were randomly allocated to the 16 groups. This was thus a prospective, randomized, blinded, placebo-controlled four-arm study (45-50 days) with the two T47D and two MCF7 xenografts. Tumor volumes were monitored twice weekly. RESULTS (1): In-vitro study. The strongest proliferation was with norethisterone, but only with PGRMC1-transfected cells. There was significant proliferation with dydrogesterone, but not with progesterone in the absence of estradiol. However, no increase in proliferation was achieved by adding dydrogesterone to estradiol compared with the proliferation induced with estradiol alone, in contrast to norethisterone. RESULTS (2): Xenograft main study. There was significantly faster tumor growth with norethisterone + E2 than with E2+placebo in T47D and MCF7 PGRMC1 xenografts, but not with dydrogesterone + E2 or progesterone + E2. There was less tumor growth in empty-vector xenografts, without between-group differences. CONCLUSION: PGRMC1 increases the breast-cell proliferation effects of certain progestogens, including dydrogesterone, in contrast to progesterone, but not during estradiol-induced proliferation, either in vitro or in a xenograft animal model, in contrast to norethisterone. Thus the proliferative potency of dydrogesterone may be similar to that of progesterone. Clinical studies in women overexpressing PGRMC1 are recommended.
Asunto(s)
Neoplasias de la Mama/metabolismo , Proliferación Celular/efectos de los fármacos , Proteínas de la Membrana/metabolismo , Progestinas/farmacología , Receptores de Progesterona/metabolismo , Androstenos/farmacología , Animales , Acetato de Ciproterona/farmacología , Didrogesterona/farmacología , Estradiol/farmacología , Femenino , Xenoinjertos , Humanos , Técnicas In Vitro , Células MCF-7 , Megestrol/análogos & derivados , Megestrol/farmacología , Ratones , Ratones Desnudos , Nandrolona/análogos & derivados , Nandrolona/farmacología , Noretindrona/farmacología , Progesterona/farmacología , Estudios ProspectivosRESUMEN
OBJECTIVES: This observational, multicentre, prospective phase IV study examined change in health-related quality of life (QOL) from baseline to 6 months in women initiating combined oral contraception (COC) based on natural estrogen. METHODS: Eligible women attending a baseline and 6-month gynaecology appointment belonged to one of three groups: group 1 used barrier contraception (condoms) and elected to continue this method; group 2 used condoms and elected to switch to COC based on natural estrogen; group 3 used COC based on ethinylestradiol and elected to switch to COC based on natural estrogen. The Spanish Society of Contraception (SEC)-QOL scale assessed health-related QOL. Secondary outcomes included symptoms of premenstrual syndrome, intermenstrual bleeding, duration and intensity of menstrual bleeding, contraception continuation rate, and tolerability. RESULTS: A total of 857 women were enrolled and 785 completed the study. Group 2 (n = 224 completed) had significantly lower SEC-QOL global and dimension scores at baseline and significantly greater increases in SEC-QOL from baseline to 6 months compared with groups 1 (n = 72) and 3 (n = 489). Group 3 reported a similar SEC-QOL score to that of group 1 at baseline but showed significantly greater improvement in SEC-QOL global and psychological scores from baseline to 6 months. Among women receiving COC based on natural estrogen, the contraception continuation rate was 713/780 (91.4%); treatment-related adverse events were reported by 13/780 (1.7%). CONCLUSIONS: Improved SEC-QOL after 6 months was found in women who were dissatisfied with their current contraception at baseline and chose to switch to COC based on natural estrogen.
Asunto(s)
Anticonceptivos Orales Combinados/uso terapéutico , Etinilestradiol/uso terapéutico , Megestrol/análogos & derivados , Nandrolona/análogos & derivados , Satisfacción del Paciente , Calidad de Vida , Adolescente , Adulto , Condones/estadística & datos numéricos , Anticonceptivos Orales Combinados/efectos adversos , Etinilestradiol/efectos adversos , Femenino , Humanos , Megestrol/efectos adversos , Megestrol/uso terapéutico , Metrorragia/inducido químicamente , Persona de Mediana Edad , Nandrolona/efectos adversos , Nandrolona/uso terapéutico , Síndrome Premenstrual/inducido químicamente , Estudios Prospectivos , Adulto JovenRESUMEN
Endocrine disruptors in water are contaminants of emerging concern due to the potential risks they pose to the environment and to the aquatic ecosystems. In this study, a solar photocatalytic treatment process in a pilot-scale compound parabolic collector (CPC) was used to remove commercial estradiol formulations (17-ß estradiol and nomegestrol acetate) from water. Photolysis alone degraded up to 50% of estradiol and removed 11% of the total organic carbon (TOC). In contrast, solar photocatalysis degraded up to 57% of estrogens and the TOC removal was 31%, with 0.6 g/L of catalyst load (TiO2 Aeroxide P-25) and 213.6 ppm of TOC as initial concentration of the commercial estradiols formulation. The adsorption of estrogens over the catalyst was insignificant and was modeled by the Langmuir isotherm. The TOC removal via photocatalysis in the photoreactor was modeled considering the reactor fluid-dynamics, the radiation field, the estrogens mass balance, and a modified Langmuir-Hinshelwood rate law, that was expressed in terms of the rate of photon adsorption. The optimum removal of the estrogens and TOC was achieved at a catalyst concentration of 0.4 g/L in 29 mm diameter tubular CPC reactors which approached the optimum catalyst concentration and optical thickness determined from the modeling of the absorption of solar radiation in the CPC, by the six-flux absorption-scattering model (SFM).
Asunto(s)
Anticonceptivos Orales/química , Estradiol/química , Megestrol/análogos & derivados , Procesos Fotoquímicos , Energía Solar , Agua/química , Catálisis , Megestrol/químicaRESUMEN
OBJECTIVE: Since its introduction 50 years ago, the contraceptive pill has continuously evolved to decrease the risk of venous thromboembolism (VTE) associated with its use. An increased risk of VTE still remains, however. Other concerns, such as effects on lipid and carbohydrate metabolism, have also been reported. In this study we compared two reference combined oral contraceptives (COCs) containing ethinylestradiol (EE)/levonorgestrel (LNG) and EE/drospirenone (DRSP) with COCs containing estradiol (E2) (estradiol valerate [E2V]/dienogest [DNG] and E2/nomegestrol acetate [NOMAC]). They were evaluated according to their influence on recognised haemostatic and metabolic markers. METHODS: A literature search of the MEDLINE/PubMed database was conducted for head-to-head studies. EE/LNG was chosen as the comparator pill. RESULTS: The haemostatic impact of E2 pills and EE/LNG has been extensively compared, in contrast to that of EE/DRSP and EE/LNG. Changes in haemostatic and metabolic marker levels between EE/LNG and E2V/DNG were generally not statistically significant. E2/NOMAC showed statistically significantly favourable results on haemostatic markers and had a neutral effect on carbohydrate and lipid metabolism when compared with EE/LNG. CONCLUSION: E2/NOMAC exhibits less haemostatic and metabolic impact than EE/LNG and other COCs, suggesting that it may be a promising candidate to reduce residual VTE risk associated with COC use. Confirmation from a well-powered prospective clinical trial is, however, needed.
Asunto(s)
Metabolismo de los Hidratos de Carbono/efectos de los fármacos , Anticonceptivos Orales Combinados/farmacología , Hemostasis/efectos de los fármacos , Metabolismo de los Lípidos/efectos de los fármacos , Androstenos/farmacología , Combinación de Medicamentos , Quimioterapia Combinada , Estradiol/análogos & derivados , Estradiol/farmacología , Estrógenos/farmacología , Etinilestradiol/farmacología , Femenino , Humanos , Levonorgestrel/farmacología , Megestrol/análogos & derivados , Megestrol/farmacología , Nandrolona/análogos & derivados , Nandrolona/farmacología , Tromboembolia Venosa/inducido químicamenteRESUMEN
Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. At dosages of 1.5mg/day or more, NOMAC effectively suppresses gonadotropic activity and ovulation in women of reproductive age. Hemostasis, lipids and carbohydrate metabolism remain largely unchanged. In normal and cancerous human breast cells, NOMAC has shown favorable effects on estrogen metabolism. Like natural progesterone (but in contrast to some other synthetic progestogens), it does not appear stimulate the proliferation of cancerous breast cells. While there has been some experience of the use of NOMAC in combination with estrogens as a hormone replacement therapy, most of the data on the compound are reported in the context of its inclusion as a component of a new contraceptive pill comprising 2.5mg NOMAC combined with 1.5mg estradiol. Because of its strong endometrial efficacy, and due to its high antigonadotropic activity and long elimination half-life (about 50h), the contraceptive efficacy of the new pill is maintained even when dosages are missed. Furthermore, for the first time with a monophasic 24/4 regimen containing estradiol, cyclical stability can be achieved comparable with that obtained using pills containing ethinyl estradiol and progestogens like levonorgestrel or drospirenone. The addition of NOMAC to estradiol means that the beneficial effects of estrogen are not lost, which is of especial importance in relation to the cardiovascular system. On the basis both of its pharmacology and of studies performed during the development of the NOMAC/estradiol pill, involving some 4000 women in total, good long-term tolerability can be expected for NOMAC, although its safety profile is still to be fully ascertained, as the clinical endpoint studies are yet to be completed.
Asunto(s)
Anticonceptivos Orales/farmacología , Estrógenos/metabolismo , Megestrol/análogos & derivados , Ciclo Menstrual/efectos de los fármacos , Ovulación/efectos de los fármacos , Congéneres de la Progesterona/farmacología , Progestinas/farmacología , Antagonistas de Andrógenos/farmacología , Endometrio/efectos de los fármacos , Femenino , Gonadotropinas/metabolismo , Humanos , Megestrol/farmacología , Norprogesteronas/farmacologíaRESUMEN
No evidence of an advantage over standard oestrogen-progestin combinations, but as many serious adverse effects as with ethinylestradiol + drospirenone.
Asunto(s)
Androstenos/uso terapéutico , Anticonceptivos Orales Combinados/uso terapéutico , Estradiol/uso terapéutico , Etinilestradiol/uso terapéutico , Megestrol/análogos & derivados , Androstenos/administración & dosificación , Androstenos/efectos adversos , Anticonceptivos Orales Combinados/administración & dosificación , Anticonceptivos Orales Combinados/efectos adversos , Quimioterapia Combinada , Estradiol/administración & dosificación , Estradiol/efectos adversos , Etinilestradiol/administración & dosificación , Etinilestradiol/efectos adversos , Femenino , Humanos , Megestrol/administración & dosificación , Megestrol/efectos adversos , Megestrol/uso terapéuticoRESUMEN
OBJECTIVES: Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due to depleted ovarian follicle reserve. DESIGN: It was a case series study that included women 18-50 years old who were treated for malignancy with gonadotoxic chemioradiotherapy. We have measured blood hormonal levels of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and progesterone within one month of various hormone replacement therapy (HRT). RESULTS: We have observed different kind of hormonal reaction according to FSH, LH, estradiol and progesterone levels due to various hormonal replacement therapy. The administration of various HRT regimens presented with a decrease in the blood concentration of estradiol E2 and progesterone and a concomitant increase of FSH and LH. These findings demonstrate a shift to physiological ranges and a simultaneous improvement of symptoms associated with CI-POF. CONCLUSIONS: The most appropriate therapy needs to be selected according to the patient's alleviation of symptoms and correction of blood hormone levels.
Asunto(s)
Quimioradioterapia/efectos adversos , Neoplasias Hematológicas/terapia , Terapia de Reemplazo de Hormonas/métodos , Insuficiencia Ovárica Primaria/inducido químicamente , Insuficiencia Ovárica Primaria/tratamiento farmacológico , Adolescente , Adulto , Anticonceptivos Femeninos/administración & dosificación , Combinación de Medicamentos , Didrogesterona/administración & dosificación , Estradiol/administración & dosificación , Estradiol/sangre , Estriol/administración & dosificación , Femenino , Hormona Folículo Estimulante Humana/sangre , Humanos , Infertilidad Femenina/sangre , Infertilidad Femenina/inducido químicamente , Infertilidad Femenina/tratamiento farmacológico , Hormona Luteinizante/sangre , Acetato de Medroxiprogesterona/administración & dosificación , Megestrol/administración & dosificación , Megestrol/análogos & derivados , Persona de Mediana Edad , Folículo Ovárico/efectos de los fármacos , Insuficiencia Ovárica Primaria/sangre , Progesterona/sangre , Congéneres de la Progesterona/administración & dosificación , Adulto JovenRESUMEN
BACKGROUND: Activity of nomegestrol acetate (NOMAC), levonorgestrel (LNG), drospirenone (DRSP), dienogest (DNG) and progesterone on human steroid receptor transactivation was investigated. Ovulation inhibition by NOMAC, LNG and progesterone was tested. STUDY DESIGN: The progestogen receptor profile was determined in Chinese hamster ovary cells transfected with human progesterone B (PRB), androgen, estrogen (ER(α) and ER(ß)), glucocorticoid (GR) and mineralocorticoid (MR) receptors, respectively. Ovulation inhibition was tested in rats and monkeys. RESULTS: Agonistic potency rankings for PRB were LNG=NOMACâ«progesteroneâ«DRSP>DNG. No antagonistic activity at PRB was observed. Only LNG had androgenic activity. Antiandrogenic potency rankings were LNGâ«NOMAC>progesterone>DNG>DRSP. All agents were devoid of activity at ER(α), ER(ß) and GR. Only progesterone, DRSP and LNG had anti-MR activity. The NOMAC dose inhibiting ovulation at 50% ranged from 0.14 mg/kg (monkey) to 1.25 to 5.0 mg/kg (rat). CONCLUSION: Nomegestrol acetate is a selective progestogen and a potent inhibitor of ovulation in the rat and monkey.
Asunto(s)
Megestrol/análogos & derivados , Ovulación/efectos de los fármacos , Congéneres de la Progesterona/farmacología , Receptores de Esteroides/agonistas , Animales , Células CHO , Cricetinae , Cricetulus , Femenino , Humanos , Macaca fascicularis , Megestrol/farmacología , Ratas , Ratas Wistar , Receptores de Esteroides/antagonistas & inhibidoresRESUMEN
BACKGROUND: In postmenopausal women, an increase in insulin resistance is associated with an increased risk of diabetes, cardiovascular disease and breast cancer. Hormone replacement therapy (HRT) can reduce insulin resistance and coffee use is reported to decrease the incidence of diabetes. The aim of our study was to assess possible concurrent effects of HRT and espresso coffee intake on insulin resistance and on interdependent nutritional and clinical features. METHODS: A total of 478 healthy postmenopausal, non-diabetic women (aged 54.5 +/- 4.2 years) were studied: 360 had been on HRT for at least 2 years and 118 were not treated. Insulin resistance was assessed by a conventional homeostasis model (HOMA-IR). RESULTS: Insulin resistance is directly related to body mass index (p < 0.0001), and not with age and blood pressure; hypertensive menopausal women have a slightly higher body mass index but the same degree of insulin resistance as normotensive women. Women on HRT show lower insulin resistance, but not lower prevalence of arterial hypertension. Coffee use is associated with a decrease in insulin resistance in non-obese women receiving HRT, but not in other subsets. CONCLUSIONS: The combination of coffee consumption and HRT could lower insulin resistance in postmenopausal women. In overweight women, greater insulin sensitivity is associated with intake of espresso coffee and not with HRT; in normal weight women, only HRT is associated with lower insulin resistance.
Asunto(s)
Café , Terapia de Reemplazo de Estrógeno , Resistencia a la Insulina , Posmenopausia , Índice de Masa Corporal , Anticonceptivos Sintéticos Orales/administración & dosificación , Estudios Transversales , Estradiol/administración & dosificación , Estrógenos/administración & dosificación , Femenino , Humanos , Hipertensión/epidemiología , Megestrol/administración & dosificación , Megestrol/análogos & derivados , Persona de Mediana EdadRESUMEN
AIM: The purpose of this paper was to estimate the effectiveness of the use of acetate nomegestrol in relation to indicator hematochemical parameters and bone mineral density (BMD) regarding patients in physiological menopause treated with hormone replacement therapy (HRT), compared to patients in surgical menopause treated with HRT by only administering transdermally hemi hydrate estradiol (estrogen replacement therapy, ERT). METHODS: Sixty women in menopause for at least 6 months ago, aged between 40 and 55 years, were recruited. Thirty of them were given HRT with acetate nomegestrol, and 30 were given only ERT, because they were subjected to general hysterectomy with bilateral adnexectomy. The standards for inclusion were: level of FSH >or= to 30 UI beta-estradiol Asunto(s)
Densidad Ósea/efectos de los fármacos
, Estradiol/uso terapéutico
, Megestrol/análogos & derivados
, Menopausia/efectos de los fármacos
, Adulto
, Biomarcadores/sangre
, Terapia de Reemplazo de Estrógeno/métodos
, Estrógenos/sangre
, Femenino
, Hormona Folículo Estimulante/sangre
, Estudios de Seguimiento
, Humanos
, Megestrol/uso terapéutico
, Menopausia/sangre
, Persona de Mediana Edad
, Calidad de Vida
, Resultado del Tratamiento
RESUMEN
OBJECTIVE: To evaluate total and site-specific bone mineral density (BMD) and serum leptin levels in postmenopausal women treated with a calcium supplement and in postmenopausal women receiving estrogen plus progestin therapy. DESIGN: Forty-four women were randomized to receive either calcium supplementation (group A, n = 22) or transdermal 17beta-estradiol at a dose of 50 mug/day in a continuous regimen and nomegestrol at a dose of 5 mg/day for 12 days per month in a sequential regimen (group B, n = 22). All women underwent dual-energy x-ray absorptiometry determination of BMD and blood sampling in the morning at the beginning of the study and after 12 months. Leptin was determined by radioimmunoassay in all samples. RESULTS: After 12 months, serum leptin levels were significantly higher in group A (control) in comparison with group B and baseline values, whereas both total and pelvic BMDs were significantly lower in group A in comparison with group B and baseline values. At baseline, a significant correlation was found between leptin levels, body mass index, and total-body BMD. After 12 months, leptin was still correlated to body mass index in both groups, but the association with BMD was lost. CONCLUSIONS: This study confirms previous evidence of a significant correlation between serum leptin and BMD in early postmenopausal women. Furthermore, this correlation is lost over time during the progression of the postmenopausal period, independently from the administration of estrogen-progestin therapy. Further studies and longer follow-up periods are needed to better understand theses issues.
Asunto(s)
Conservadores de la Densidad Ósea/administración & dosificación , Calcio de la Dieta/metabolismo , Estradiol/administración & dosificación , Leptina/sangre , Megestrol/análogos & derivados , Posmenopausia/metabolismo , Absorciometría de Fotón , Densidad Ósea , Relación Dosis-Respuesta a Droga , Terapia de Reemplazo de Estrógeno , Femenino , Estudios de Seguimiento , Humanos , Megestrol/administración & dosificación , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
OBJECTIVE: To confirm the effect of postmenopausal hypoestrogenism and hormone therapy (HT) on body composition and serum leptin levels. DESIGN: Prospective, longitudinal study evaluating body composition (body mass index, and total and percent fat mass and lean mass measured at the arms, legs and trunk) with dual-energy x-ray absorptiometry and serum leptin levels by radioimmunoassay in 44 healthy postmenopausal women randomized to receive either no treatment (n = 22) or transdermal 17beta-estradiol (50 microg/day) in continuous regimen and nomegestrol (5 mg/day for 12 days/month) in a sequential regimen (n = 22). RESULTS: One year after the beginning of the study, in untreated women, total and trunk fat mass and percent fat were significantly increased, whereas trunk lean mass was significantly decreased. On the contrary, women treated with HT did not show any significant difference in body composition parameters. In untreated women, serum leptin levels were significantly increased at the end of the study in comparison with baseline values. Serum leptin levels at the other times evaluated were not significantly different from baseline values. In women treated with HT, serum leptin levels did not show significant changes throughout the study. CONCLUSIONS: Untreated postmenopausal women show an increase in total and percent fat mass and a centralization of fat distribution. Serum leptin levels parallel this increase, resulting in significantly higher levels 1 year after the study. Women treated with HT are protected against these changes. This may represent a protective mechanism against cardiovascular diseases.
Asunto(s)
Composición Corporal , Estradiol/farmacología , Terapia de Reemplazo de Estrógeno , Leptina/sangre , Megestrol/análogos & derivados , Megestrol/farmacología , Posmenopausia/fisiología , Femenino , Humanos , Persona de Mediana Edad , Congéneres de la Progesterona/farmacología , Estudios Prospectivos , RadioinmunoensayoRESUMEN
OBJECTIVES: Previous studies indicate that low-dose hormone replacement therapy (LD-HRT) can relieve vasomotor symptoms and prevent spine bone loss. METHODS: In the present study, we evaluated the effects of a low dose of conjugated equine estrogens (CEE; 0.3 mg) associated with different progestins in continuous combined scheme [2.5 mg of medroxyprogesterone acetate (n=25), 5 mg dydrogesterone (n=27), 2.5 mg nomegestrol (n=11)] as single group, on femur bone mineral density (BMD) and bone metabolism in young postmenopausal women (Asunto(s)
Terapia de Reemplazo de Estrógeno
, Megestrol/análogos & derivados
, Osteoporosis Posmenopáusica/tratamiento farmacológico
, Quimioterapia Combinada
, Didrogesterona/uso terapéutico
, Estrógenos Conjugados (USP)/uso terapéutico
, Femenino
, Fémur
, Humanos
, Megestrol/uso terapéutico
, Persona de Mediana Edad
, Osteoporosis Posmenopáusica/prevención & control
, Congéneres de la Progesterona/uso terapéutico
, Estudios Prospectivos
RESUMEN
In vivo experiments on rats and rabbits showed that megestrol caproate, a 17-alpha-hydroxyprogesterone derivative exhibits 10-fold higher gestagenic activity compared to progesterone and possesses no androgenic, anabolic, and estrogenic activities.
Asunto(s)
Anticonceptivos/farmacología , Megestrol/farmacología , Congéneres de la Progesterona/farmacología , Animales , Relación Dosis-Respuesta a Droga , Femenino , Masculino , Megestrol/análogos & derivados , Conejos , Ratas , Ratas WistarRESUMEN
OBJECTIVE: To study the adhesion molecule pattern in postmenopausal women who were not receiving hormone replacement therapy (HRT), HRT users, and fertile women. DESIGN: Case-control study. SETTING: Second University of Naples, Naples, Italy. PATIENT(S): Fifty healthy naturally postmenopausal women and 20 fertile women. INTERVENTION(S): Twenty-six women received no HRT and 24 received continuous transdermal 17 beta-estradiol, 0.05 mg/d, plus oral acetate nomegestrol, 5 mg/d. MAIN OUTCOME MEASURE(S): Levels of the soluble forms of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin. RESULT(S): Women who did not received HRT showed a trend toward higher levels of soluble E-selectin and had significantly higher levels of soluble P-selectin than did fertile women. Levels of soluble E-selectin and soluble P-selectin were significantly lower in HRT users than in nonusers. Levels of VCAM-1 levels were significantly higher in HRT users than in fertile women, but no significant differences in CAM concentrations were found between the other groups. CONCLUSION(S): Menopause may lead to increased levels of soluble E- and soluble P-selectin, whereas long-term HRT is associated with lower selectin concentrations. This suggests that HRT may have a beneficial effect on endothelial function.
Asunto(s)
Selectina E/sangre , Terapia de Reemplazo de Hormonas , Megestrol/análogos & derivados , Selectina-P/sangre , Posmenopausia/sangre , Administración Cutánea , Estudios de Casos y Controles , Selectina E/biosíntesis , Estradiol/administración & dosificación , Femenino , Humanos , Molécula 1 de Adhesión Intercelular/biosíntesis , Molécula 1 de Adhesión Intercelular/sangre , Megestrol/administración & dosificación , Selectina-P/biosíntesis , Molécula 1 de Adhesión Celular Vascular/biosíntesis , Molécula 1 de Adhesión Celular Vascular/sangreRESUMEN
The experience of 6 million Norplant users has led to several more advanced implants. Implanon is a single-rod implant system containing a low androgenic progestin and requires 1 to 2 minutes for insertion and removal. Like other implants, Implanon prevents pregnancy by changing the character of the cervical mucus and interfering with luteal function. Unlike Norplant, though, Implanon is designed to prevent ovulation for the full duration of use. Implant contraception has several advantages over other types of contraception including high efficacy, minimal required maintenance, absence of estrogen, and rapid return of fertility after discontinuation. Implants can be a good choice for adolescents; women with hypertension, diabetes, anemia, endometriosis, or other medical problems; and women who are breast-feeding. Irregular bleeding is the most common adverse effect of implants and can be treated with several medication regimens. Preinsertion counseling, however, is the most important factor in ensuring satisfaction with implants. Unfortunately, no implant system is currently available in the United States since August 2000, but Implanon is expected to reach the U.S. market within the next 2 years.
Asunto(s)
Anticonceptivos Femeninos/administración & dosificación , Desogestrel , Implantes de Medicamentos/administración & dosificación , Megestrol/análogos & derivados , Congéneres de la Progesterona/administración & dosificación , Moco del Cuello Uterino/efectos de los fármacos , Ensayos Clínicos como Asunto , Anticonceptivos Femeninos/economía , Anticonceptivos Femeninos/farmacología , Consejo , Endometrio/efectos de los fármacos , Femenino , Humanos , Levonorgestrel/administración & dosificación , Levonorgestrel/farmacología , Megestrol/administración & dosificación , Megestrol/farmacología , Norprogesteronas/administración & dosificación , Norprogesteronas/farmacología , Ovulación/efectos de los fármacos , Satisfacción del Paciente , Embarazo , Congéneres de la Progesterona/economía , Congéneres de la Progesterona/farmacología , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo , Compuestos de Vinilo/administración & dosificación , Compuestos de Vinilo/farmacologíaRESUMEN
Different cohort studies have shown that HRT decreases the risk of cardio-vascular (C-V) disease and the risk of bone fracture by 30 to 50%. The only controlled study (HERS study) did not show any benefit of HRT with estradiol and medroxyprogesterone (MPG) in secondary prevention. The beneficial effect of estrogens on coronary dilatation and on HDL cholesterol could be attenuated by some progestogens such as MPG but not by nomegestrol acetate. In this framework, the comparative metabolic effects of different progestogens and tibolone are described in this article. The effects of estrogens on mood and of androgens on libido are discussed. The preventive effect of estrogens on osteoporosis and on Alzheimer disease is compared to other nonhormonal treatments.